Milestone Pharmaceuticals Stock Today
| MIST Stock | USD 1.87 0.02 1.08% |
Performance12 of 100
| Odds Of DistressOver 66
|
Milestone Pharmaceuticals is selling for under 1.87 as of the 28th of November 2024; that is 1.08 percent increase since the beginning of the trading day. The stock's last reported lowest price was 1.85. Milestone Pharmaceuticals has more than 66 % chance of experiencing financial distress in the next few years of operation. However, it had a very good returns during the last 90 days. Equity ratings for Milestone Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of December 2022 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 9th of May 2019 | Category Healthcare | Classification Health Care |
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company was incorporated in 2003 and is headquartered in Montral, Canada. Milestone Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 53.33 M outstanding shares of which 454.79 K shares are now shorted by private and institutional investors with about 2.46 trading days to cover. More on Milestone Pharmaceuticals
Moving together with Milestone Stock
| 0.72 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
Moving against Milestone Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Milestone Stock Highlights
| President CEO | Joseph MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsMilestone Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Milestone Pharmaceuticals' financial leverage. It provides some insight into what part of Milestone Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Milestone Pharmaceuticals (MIST) is traded on NASDAQ Exchange in USA. It is located in 1111 Dr. Frederik-Philips Boulevard, Montreal, QC, Canada, H4M 2X6 and employs 47 people. Milestone Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 98.66 M. Milestone Pharmaceuticals conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 53.33 M outstanding shares of which 454.79 K shares are now shorted by private and institutional investors with about 2.46 trading days to cover.
Milestone Pharmaceuticals currently holds about 86.24 M in cash with (46.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.87, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Milestone Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationMilestone Pharmaceuticals maintains a total of 53.33 Million outstanding shares. Over half of Milestone Pharmaceuticals' outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Milestone Ownership Details
Milestone Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Stonepine Capital Management Llc | 2024-06-30 | 1.2 M | |
| Bml Capital Management Llc | 2024-09-30 | 1.1 M | |
| Ikarian Capital, Llc | 2024-09-30 | 466 K | |
| Altium Capital Management, Lp | 2024-09-30 | 440 K | |
| Boxer Capital Llc | 2024-09-30 | 309 K | |
| Envestnet Asset Management Inc | 2024-09-30 | 70.6 K | |
| Ancora Advisors Llc | 2024-06-30 | 60 K | |
| Squarepoint Ops Llc | 2024-06-30 | 54.7 K | |
| Atria Investments Llc | 2024-09-30 | 40.4 K | |
| Blackrock Inc | 2024-06-30 | 5 M | |
| Rtw Investments, Llc | 2024-06-30 | 3.3 M |
Milestone Pharmaceuticals Historical Income Statement
Milestone Stock Against Markets
Milestone Pharmaceuticals Corporate Management
| Anita Holz | VP Affairs | Profile | |
| Guy Rousseau | SVP Management | Profile | |
| FACC FAHA | Chief Board | Profile | |
| Jeffrey Nelson | Chief Officer | Profile | |
| Roshan Girglani | Vice Marketing | Profile |
Additional Tools for Milestone Stock Analysis
When running Milestone Pharmaceuticals' price analysis, check to measure Milestone Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Milestone Pharmaceuticals is operating at the current time. Most of Milestone Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Milestone Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Milestone Pharmaceuticals' price. Additionally, you may evaluate how the addition of Milestone Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.